Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator  by Steinhubl, Steven R. et al.
401
Abciximab (ReoPro) removal during cardiopul-
monary bypass with a hemoconcentrator
To the Editor:
Poullis and colleagues1 recently presented their results of
an ex vivo study suggesting that a hemoconcentrator could be
used to remove the platelet glycoprotein IIb/IIIa (GPIIb/IIIa)
inhibitor abciximab (c7E Fab, ReoPro) during cardiopul-
monary bypass. On the basis of their findings, they state that
the use of a hemoconcentrator would reduce the need for
platelet transfusions and decrease the risk of bleeding in
patients recently treated with abciximab undergoing coronary
bypass. However, we believe their model incorporates severe
limitations that invalidate their findings.
The investigators state that the use of a hemoconcentrator
will remove “free ReoPro from the plasma.” They support
this conclusion through studies with a model that used either
saline solution or saline plus packed red blood cells to which
abciximab was added. However, because of the pharmacoki-
netics of abciximab, this model is not representative of a
patient treated with abciximab. In a patient, abciximab binds
with very high affinity (KD = 5 nmol/L) to the platelet
GPIIb/IIIa receptor, as well as to the α
v
β3 receptor found on
endothelial and smooth muscle cells2,3; any unbound mole-
cules of this monoclonal antibody fragment are cleared rapid-
ly from the plasma by the reticuloendothelial system.
Therefore free plasma concentrations of abciximab diminish
very rapidly after the termination of an infusion, with a half-
life of about 30 minutes.4,5 Thus, although in the model
described by Poullis’s group there was free abciximab avail-
able to be removed by the hemoconcentrator, this was
because they used solutions free of platelets or any other cells
to which the abciximab could bind. In a patient treated with
abciximab, there would be no unbound molecule available for
removal, and a hemoconcentrator would be of no benefit.
Aggressive platelet inhibition with GPIIb/IIIa inhibitors in
patients needing urgent cardiac surgery is certainly an appro-
priate concern. However, although anecdotal reports have
suggested a risk of excessive bleeding,6 results from recent
randomized trials have shown only a higher rate of platelet
transfusions in abciximab-treated patients, and, in fact, a
trend toward a decrease in death and perioperative myocar-
dial infarction compared with results in patients receiving
placebo.7
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Reply to the Editor:
We welcome the interest that our brief communication on
abciximab (ReoPro) removal1 has generated. Steinhubl,
Moore, and Lincoff raise a number of interesting issues:
First, we did not state that “a hemoconcentrator would
reduce the need for platelet transfusions and decrease the risk
of bleeding....” However, we did say that hemofiltration (1)
can remove free abciximab from a cardiopulmonary bypass
circuit, (2) can change the purpose of platelet replacement
from primarily absorbing free antibody to providing adequate
hemostasis, and (3) may result in a decreased risk of bleeding
during and after cardiac surgery. We make no claims to rever-
sal of the effect of abciximab on native platelets. However, by
implication from our results and the fact that abciximab bind-
ing is known to be a reversible process, hemofiltration may
result in at least a partial reversal of the effect of abciximab
on native platelets.2
Second, we agree that the pharmacokinetics of our study do
not match the in vivo situation. However, our aim was to
demonstrate that free abciximab could be removed with a
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